Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBT (2016 - 2021)

Historic EBT for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to $30.5 million.

  • Neurocrine Biosciences' EBT rose 15341.51% to $30.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $58.1 million, marking a year-over-year decrease of 4394.16%. This contributed to the annual value of $46.5 million for FY2019, which is 11309.46% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported EBT of $30.5 million as of Q3 2021, which was up 15341.51% from $57.5 million recorded in Q2 2021.
  • Neurocrine Biosciences' 5-year EBT high stood at $83.2 million for Q2 2020, and its period low was -$102.6 million during Q1 2019.
  • Over the past 5 years, Neurocrine Biosciences' median EBT value was $23.0 million (recorded in 2018), while the average stood at $5.8 million.
  • In the last 5 years, Neurocrine Biosciences' EBT crashed by 29366.3% in 2017 and then surged by 98110.94% in 2019.
  • Over the past 5 years, Neurocrine Biosciences' EBT (Quarter) stood at $6.9 million in 2017, then skyrocketed by 172.82% to $18.8 million in 2018, then skyrocketed by 105.46% to $38.6 million in 2019, then crashed by 247.77% to -$57.1 million in 2020, then soared by 153.42% to $30.5 million in 2021.
  • Its last three reported values are $30.5 million in Q3 2021, $57.5 million for Q2 2021, and $27.2 million during Q1 2021.